A MAVS/TICAM-1-independent interferon-inducing pathway contributes to regulation of hepatitis B virus replication in the mouse hydrodynamic injection model

Journal of Innate Immunity

Volumn 7, Issue 1, 2015, Pages 47-58

  Leong, Chean Ring ^a   Oshiumi, Hiroyuki ^a   Okamoto, Masaaki ^a   Azuma, Masahiro ^a   Takaki, Hiromi ^a   Matsumoto, Misako ^a   Chayama, Kazuaki ^b   Seya, Tsukasa ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Hepatitis B virus regulation; Mitochondrial antiviral signaling protein; Pathogen associated molecular patterns; Toll IL 1R homology domain containing adaptor molecule 1; Type I interferon

Indexed keywords

ADAPTOR PROTEIN; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; INTERFERON RECEPTOR; INTERFERON REGULATORY FACTOR 3; INTERFERON REGULATORY FACTOR 7; MITOCHONDRIAL ANTIVIRAL SIGNALING PROTEIN; MYELOID DIFFERENTIATION FACTOR 88; RAG2 PROTEIN; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS RNA; HEPATITIS B ANTIGEN; IPS-1 PROTEIN, MOUSE; IRF3 PROTEIN, MOUSE; IRF7 PROTEIN, MOUSE; MYD88 PROTEIN, MOUSE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TICAM-1 PROTEIN, MOUSE; VESICULAR TRANSPORT ADAPTOR PROTEIN;

ADAPTIVE IMMUNITY; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; HEPATITIS B VIRUS; HYDRODYNAMICS BASED TRANSFECTION; INNATE IMMUNITY; KNOCKOUT MOUSE; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; VIRAL CLEARANCE; VIRUS IMMUNITY; VIRUS INHIBITION; VIRUS REPLICATION; ANIMAL; DISEASE MODEL; GENETICS; HEPATITIS B; IMMUNOLOGY; PHYSIOLOGY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADAPTOR PROTEINS, VESICULAR TRANSPORT; ANIMALS; DISEASE MODELS, ANIMAL; HEPATITIS B; HEPATITIS B ANTIGENS; HEPATITIS B VIRUS; INTERFERON REGULATORY FACTOR-3; INTERFERON REGULATORY FACTOR-7; MICE; MICE, KNOCKOUT; MYELOID DIFFERENTIATION FACTOR 88; SIGNAL TRANSDUCTION; VIRUS REPLICATION;

EID: 84918789184     PISSN: 1662811X     EISSN: 16628128     Source Type: Journal    
DOI: 10.1159/000365113     Document Type: Article

References (40)

1. Guidotti LG, Chisari FV: Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol 2006;1:23-61.
2. Zuckerman JN, Zuckerman AJ: Current topics in hepatitis B. J Infect 2000;41:130-136.
3. Ganem D, Prince AM: Hepatitis B virus infection - natural history and clinical consequences. N Engl J Med 2004;350:1118-1129.
4. Seeger C, Mason WS: Hepatitis B virus biology. Microbiol Mol Biol Rev 2000;64:51-68.
5. Isogawa M, Robek MD, Furuichi Y, Chisari FV: Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J Virol 2005;79:7269-7272.
6. Wu J, Lu M, Meng Z, Trippler M, Broering R, Szczeponek A, Krux F, Dittmer U, Roggendorf M, Gerken G, Schlaak JF: Toll-like receptormediated control of HBV replication by nonparenchymal liver cells in mice. Hepatology 2007;46:1769-1778.
7. Kawai T, Takahashi K, Sato S, Coban C, Kumar H, Kato H, Ishii KJ, Takeuchi O, Akira S: IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat Immunol 2005;6:981-988.
8. Akira S, Uematsu S, Takeuchi O: Pathogen recognition and innate immunity. Cell 2006;124:783-801.
9. Takeuchi O, Akira S: Innate immunity to virus infection. Immunol Rev 2009;227:75-86.
10. Oshiumi H, Matsumoto M, Funami K, Akazawa T, Seya T: TICAM-1, an adaptor molecule that participates in Toll-like receptor 3-mediated interferon-β induction. Nat Immunol 2003;4:161-167.
11. Ishikawa H, Ma Z, Barber GN: STING regulates intracellular DNA-mediated, type I interferondependent innate immunity. Nature 2009;461:788-792.
12. Cheng G: Double-stranded DNA and doublestranded RNA induce a common antiviral signaling pathway in human cells. Proc Natl Acad Sci USA 2007;104:9035-9040.
13. Ablasser A, Bauernfeind F, Hartmann G, Latz E, Fitzgerald KA, Hornung V: RIG-I-dependent sensing of poly (dA:dT) through the induction of an RNA polymerase III-transcribed RNA intermediate. Nat Immunol 2009;10:1065-1072.
14. Chiu YH, Macmillan JB, Chen ZJ: RNA polymerase III detects cytosolic DNA and induces type I interferons through the RIG-I pathway. Cell 2009;138:576-591.
15. Stetson DB, Medzhitov R: Type I interferons in host defense. Immunity 2006;25:373-381.
16. Kumar M, Jung SY, Hodgson AJ, Madden CR, Qin J, Slagle BL: Hepatitis B virus regulatory HBx protein binds to adaptor protein IPS-1 and inhibits the activation of beta interferon. J Virol 2011;85:987-995.
17. Wei C, Ni C, Song T, Liu Y, Yang X, Zheng Z, Jia Y, Yuan Y, Guan K, Xu Y, Cheng X, Zhang Y, Wang Y, Wen C, Wu Q, Shi W, Zhong H: The hepatitis B virus X protein disrupts innate immunity by down regulating mitochondrial antiviral signaling protein. J Immunol 2010;185:1158-1168.
18. Yu S, Chen J, Wu M, Chen H, Kato N, Yuan Z: Hepatitis B virus polymerase inhibits RIGI- and Toll-like receptor 3-mediated beta interferon induction in human hepatocytes through interference with interferon regulatory factor 3 activation and dampening of the interaction between TBK1/IKKepsilon and DDX3. J Gen Virol 2010;91:2080-2090.
19. Oshiumi H, Okamoto M, Fujii K, Kawanishi T, Matsumoto M, Koike S, Seya T: The TLR3/TICAM-1 pathway is mandatory for innate immune responses to poliovirus infection. J Immunol 2011;187:5320-5327.
20. Akazawa T, Ebihara T, Okuno M, Okuda Y, Shingai M, Tsujimura K, Takahashi T, Ikawa M, Okabe M, Inoue N, et al: Antitumor NK activation induced by the Toll-like receptor 3-TICAM-1 (TRIF) pathway in myeloid dendritic cells. Proc Natl Acad Sci USA 2007;104:252-257.
21. Noguchi C, Ishino H, Tsuge M, Fujimoto Y, Imamura M, Takahashi S, Chayama K: G to A hypermutation of hepatitis B virus. Hepatology 2005;41:626-633.
22. Tian Y, Chen WL, Kuo CF, Ou JH: Viral-loaddependent effects of liver injury and regeneration on hepatitis B virus replication in mice. J Virol 2012;86:9599-9605.
23. Yang PL, Althage A, Chung J, Chisari FV: Hydrodynamic injection of viral DNA: a mouse model of acute hepatitis B virus infection. Proc Natl Acad Sci USA 2002;99:13825-13830.
24. Aly HH, Oshiumi H, Shime H, Matsumoto M, Wakita T, Shimotohno K, Seya T: Development of mouse hepatocyte lines permissive for hepatitis C virus (HCV). PLoS One 2011;6:e21284.
25. Honda K, Taniguchi T: IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat Rev Immunol 2006;6:644-658.
26. Wang X, Li Y, Mao A, Li C, Tien P: Hepatitis B virus X protein suppresses virus-triggered IRF3 activation and IFN-beta induction by disrupting the VISA-associated complex. Cell Mol Immunol 2010;7:341-348.
27. Kawai T, Akira S: Innate immune recognition of viral infection. Nat Immunol 2006;7:131-137.
28. Onomoto K, Yoneyama M, Fujita T: Regulation of antiviral innate immune responses by RIG-I family of RNA helicases. Curr Top Microbiol Immunol 2007;316:193-205.
29. Matsumoto M, Oshiumi H, Seya T: Antiviral responses induced by the TLR3 pathway. Rev Med Virol 2011, DOI: 10.1002/rmv. 680.
30. Diebold SS: Recognition of viral singlestranded RNA by Toll-like receptors. Adv Drug Deliv Rev 2008;60:813-823.
31. Paludan SR, Bowie AG: Immune sensing of DNA. Immunity 2013;38:870-880.
32. Ishikawa H, Barber GN: The STING pathway and regulation of innate immune signaling in response to DNA pathogens. Cell Mol Life Sci 2011;68:1157-1165.
33. Suzuki T, Oshiumi H, Miyashita M, Aly HH, Matsumoto M, Seya T: Cell type-specific subcellular localization of phospho-TBK1 in response to cytoplasmic viral DNA. PLoS One 2013;8:e83639.
34. Bertoletti A, Gehring AJ: The immune response during hepatitis B virus infection. J Gen Virol 2006;87:1439-1449.
35. Hoshino K, Sasaki I, Sugiyama T, Yano T, Yamazaki C, Yasui T, Kikutani H, Kaisho T: Critical role of IkappaB Kinase alpha in TLR7/9-induced type I IFN production by conventional dendritic cells. J Immunol 2010;184:3341-3345.
36. Hoshino K, Sugiyama T, Matsumoto M, Tanaka T, Saito M, Hemmi H, Ohara O, Akira S, Kaisho T: IkappaB kinase-alpha is critical for interferon-alpha production induced by Toll-like receptors 7 and 9. Nature 2006;440:949-953.
37. Swiecki M, Wang Y, Vermi W, Gilfillan S, Schreiber RD, Colonna M: Type I interferon negatively controls plasmacytoid dendritic cell numbers in vivo. J Exp Med 2011;208:2367-2374.
38. Lv S, Wang J, Dou S, Yang X, Ni X, Sun R, Tian Z, Wei H: Nanoparticles encapsulating HBV-CpG induce therapeutic immunity against hepatitis B virus infection. Hepatology 2014;59:385-394.
39. Ter Borg MJ, Hansen BE, Bigot G, Haagmans BL, Janssen HL: ALT and viral load decline during PEG-IFN alpha-2b treatment for HBeAg-positive chronic hepatitis B. J Clin Virol 2008;42:160-164.
40. Tan AT, Hoang LT, Chin D, Rasmussen E, Lopatin U, Hart S, Bitter H, Chu T, Gruenbaum L, Ravindran P, Zhong H, Gane E, Lim SG, Chow WC, Chen PJ, Petric R, Bertoletti A, Hibberd ML: Reduction of HBV replication prolongs the early immunological response to IFNα therapy. J Hepatol 2014;60:54-61.